Literature DB >> 24792824

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Martin Johnson1, Magdalena Kozielska, Venkatesh Pilla Reddy, An Vermeulen, Hugh A Barton, Sarah Grimwood, Rik de Greef, Geny M M Groothuis, Meindert Danhof, Johannes H Proost.   

Abstract

OBJECTIVES: Dopamine D2 receptor occupancy (D2RO) is the major determinant of efficacy and safety in schizophrenia drug therapy. Excessive D2RO (>80%) is known to cause catalepsy (CAT) in rats and extrapyramidal side effects (EPS) in human. The objective of this study was to use pharmacokinetic and pharmacodynamic modeling tools to relate CAT with D2RO in rats and to compare that with the relationship between D2RO and EPS in humans.
METHODS: Severity of CAT was assessed in rats at hourly intervals over a period of 8 h after antipsychotic drug treatment. An indirect response model with and without Markov elements was used to explain the relationship of D2RO and CAT.
RESULTS: Both models explained the CAT data well for olanzapine, paliperidone and risperidone. However, only the model with the Markov elements predicted the CAT severity well for clozapine and haloperidol. The relationship between CAT scores in rat and EPS scores in humans was implemented in a quantitative manner. Risk of EPS not exceeding 10% over placebo correlates with less than 86% D2RO and less than 30% probability of CAT events in rats.
CONCLUSION: A quantitative relationship between rat CAT and human EPS was elucidated and may be used in drug discovery to predict the risk of EPS in humans from D2RO and CAT scores measured in rats.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792824     DOI: 10.1007/s11095-014-1358-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 3.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

4.  Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats.

Authors:  T J Parker; O E Della Pasqua ; E Loizillon; C Chezaubernard; R Jochemsen; M Danhof
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Authors:  Magdalena Kozielska; Martin Johnson; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2012-03-22       Impact factor: 4.200

6.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

7.  Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.

Authors:  Christina Kurre Olsen; Lise Tøttrup Brennum; Mads Kreilgaard
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

8.  Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder.

Authors:  K Ito; Mm Hutmacher; J Liu; R Qiu; B Frame; R Miller
Journal:  Clin Pharmacol Ther       Date:  2008-02-06       Impact factor: 6.875

9.  Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Authors:  V Pilla Reddy; K J Petersson; A A Suleiman; A Vermeulen; J H Proost; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Authors:  Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.410

View more
  3 in total

1.  Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens.

Authors:  Su Xu; Rao P Gullapalli; Douglas O Frost
Journal:  Schizophr Res       Date:  2014-12-05       Impact factor: 4.939

2.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

Review 3.  Update on schizophrenia and bipolar disorder: focus on cariprazine.

Authors:  Rona Jeannie Roberts; Lillian Jan Findlay; Peggy L El-Mallakh; Rif S El-Mallakh
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-25       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.